ArticleSignal transduction and targeted therapy2025

Preclinical and first-in-human of purinostat mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed/refractory multiple myeloma and lymphoma.

Linyu Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.